Circulating endothelial progenitor cells as a marker of left ventricular pump function in ischemic chronic heart failure
DOI:
https://doi.org/10.14739/2409-2932.2017.3.113561Keywords:
heart failure, preserved left ventricular function, biomarkers, endothelial progenitor cellsAbstract
The goal of the study was to explore whether the quantity of endothelial progenitor cells (EPCs) associates with ischemic chronic heart failure (CHF) phenotypes.
Materials and methods. Inclusion criteria met 82 patients with ischemic CHF. Sick persons with global left ventricular ejection fraction >40 % were graded as the HFpEF group (n = 39) and others with ≤40 % as the HFrEF group (n = 43). The levels of biomarkers in serum were measured at starting point. The method of flow cytometry was used for predictably distinguishing circulating cell subsets depending on expression of CD45, CD34, CD14, Tie-2, and CD309 antigens.
Results. In multivariate logistic regression model galectin-3 (R2 = 0.67;P = 0.012), T2DM (R2 = 0.26;P=0.001), previous MI (R2 = 0.17;P = 0.012), obesity (R2 = 0.22;P = 0.001), CD14+CD309+ cells (R2 = 0.058;P = 0.001), and CD14+СD309+Tie-2+ cells (R2 = 0.044;P = 0.028), NT-proBNP (R2 = 0.11;P = 0.046) were found as autonomous predictors of HFpEF. With help of multivariate Cox-regression analysis we found out, that NT-proBNP (OR 1.08; 95 % CI = 1.03–1.12; P = 0.001) and number of CD14+CD309+ cells (OR 1.07; 95 % CI = 1.02–1.11; P = 0.05) were independent predictors for HFpEF. The quantity of CD14+CD309+ cells added to NT-proBNP had more exact predictive value (OR 1.10; 95 % CI = 1.04–1.14; P = 0.001) than these biomarkers unaccompanied.
Conclusion: quantity of NT-proBNP added to CD14+CD309+ cells, cardiovascular risk influences and clinical information exhibited the best discriminate importance to differentiate HFpEF from HFrEF.
References
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Blaha, M. J., et al. (2014) Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation, 129(3), e28–e292. doi: 10.1161/01.cir.0000441139.02102.80.
Dunlay, S. M., Manemann, S. M., Chamberlain, A. M., Cheville, A. L., Jiang, R., Weston, S. A., & Roger, V. L. (2015) Activities of daily living and outcomes in heart failure. Circ Heart Fail., 8(2), 261–7. doi: 10.1161/CIRCHEARTFAILURE.114.001542.
McMurray, J. J., Adamopoulos, S., Anker, S. D., Auricchio, A., Bohm, M., Dickstein, K., et al. (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail., 14(8), 803–69. doi: 10.1093/eurjhf/hfs105.
Fujisue, K., Sugiyama, S., Matsuzawa, Y., Akiyama, E., Sugamura, K., Matsubara, J., et al. (2015) Prognostic Significance of Peripheral Microvascular Endothelial Dysfunction in Heart Failure With Reduced Left Ventricular Ejection Fraction. Circ J. 79(12), 2623–31. doi: 10.1253/circj.CJ-15-0671.
Berezin, A. E. (2015) Endothelial Derived Micro Particles: Biomarkers for Heart Failure Diagnosis and Management. J Clin Trial Cardiol., 2(3), 1–3.
McMurray, J.J., Adamopoulos, S., Anker, S.D., Auricchio, A., Bohm, M., Dickstein, K., et al., 2012. ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail. 14 (8), 803–869.
Quiñones, M. A., Douglas, P. S., Foster, E., Gorcsan, J. 3rd, Lewis, J. F., Pearlman, A. S., et al. (2003) American College of Cardiology/American Heart Association clinical competence statement on echocardiography: a report of the American College of Cardiology/American Heart Association/American College of Physicians--American Society of Internal Medicine Task Force on Clinical Competence. Circulation, 107(7), 1068–89. doi: https://doi.org/10.1161/01.CIR.0000061708.42540.47.
Tung J.W., Parks D.R., Moore W.A., et al. New approaches to fluorescence compensation and visualization of FACS data. Clin. Immunol. 2004; 110: 277-83.
Berezin A. Progenitor Cell Dysfunction: The Role of Endothelial Precursors in Heart Failure. J Biomedical Sci. 2017, 6(4): 31-33
Regueiro A, Cuadrado-Godia E, Bueno-Betí C, Diaz-Ricart M, Oliveras A, Novella S, et al. Mobilization of endothelial progenitor cells in acute cardiovascular events in the PROCELL study: time-course after acute myocardial infarction and stroke. J Mol Cell Cardiol. 2015; 80:146-55.
Berezin A. Biomarkers in heart failure. Journal of Blood & Lymph. 2017; 7 (3): 172-179
Basile DP, Yoder MC. Circulating and tissue resident endothelial progenitor cells. J Cell Physiol. 2014; 229(1):10-6.
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
